Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F Seymour,Jenny Qun Wu,Relja Popovic,Barbara Eichhorst,Peter Hillmen,Thomas J Kipps,Anton W Langerak,Carolyn Owen,Julie Dubois,Clemens Mellink,Anne-Marie Van Der Kevie-Kersemaekers,Fengjiao Dunbar,Yanwen Jiang,Brenda Chyla,Michelle Boyer,Maria Thadani-Mulero,Marcus Lefebure,Rosemary Harrup,Arnon P Kater

doi:10.1182/blood-2021-147731

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F Seymour, Jenny Qun Wu + Show 17 more

Open Access

https://doi.org/10.1182/blood-2021-147731

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 5

Affiliation: Royal Melbourne Hospital, AbbVie (United States), University of Cologne, St James's University Hospital, Erasmus MC, University of Calgary, Amsterdam University Medical Centers, Roche (United Kingdom), University of Tasmania

#Equity Holder In Publicly-traded Company #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Full Text